Esther Rajavelu

Esther Rajavelu

President and Chief Executive Officer, Chief Financial Officer, Chief Business Officer and TreasureratSpero Therapeutics· In proxies 2023–2025

Pay in FY2025+141% from the year before · Spero Therapeutics stock +126.2% the same year

Esther Rajavelu was paid $2.1M in FY2025 (Dec), up 141%. Spero Therapeutics stock rose 126.2% that year.

Pay$100 in the stock at the end of FY22 → $135
Pay is from the Summary Compensation Table of each Spero Therapeutics proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Spero TherapeuticsPublic company · 3 yr
    • President and Chief Executive Officer, Chief Financial Officer, Chief Business Officer and Treasurer2023 – Present · 3 yrStock in role -25%

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?